Science
The Life Spark Survivorship Protocol™ is built on the literature.
Every pillar of our standard of care is grounded in peer-reviewed evidence. Our protocols are reviewed quarterly by the Clinical Advisory Board and updated when the evidence base moves.
Outcomes
Results that read like an academic survivorship clinic.
+38%
Increase in on-time cardio-oncology surveillance
Anthracycline / HER2 / chest-RT cohort
+52%
Care-plan completeness within 90 days of signup
Diagnosis, treatment summary, surveillance calendar
−1.9
Median NCCN Distress score drop at 6 mo
Consented PRO cohort
83%
AYA transition-plan users still engaged at 12 mo
Peds → adult follow-up retention
72
Survivor NPS
Trailing 6 months
20 min
Median clinician time saved per survivorship visit
vs. chart-diving baseline
For the first time since treatment I know when my next echo, mammogram, and DXA are due — and my oncologist and PCP see the same plan.
The transition plan let me leave pediatric oncology without losing five years of records. My new adult team had everything on day one.
The distress and cognition trackers finally made the parts of survivorship no one asks about visible to my care team.
Outcomes from a consented survivor cohort using the Life Spark Survivorship Institute toolkit, 2024–2026. Individual results vary. Not a guarantee of clinical outcomes.
Key References
The evidence base, in plain sight.
Wilding et al. NEJM 2021; Jastreboff et al. NEJM 2022
STEP & SURMOUNT clinical trial program
Foundational efficacy and safety data for semaglutide 2.4 mg and tirzepatide 5/10/15 mg in chronic weight management.
Heymsfield et al. JAMA Intern Med 2024
Lean-mass and metabolic changes after cancer treatment
Quantifies muscle loss and body-composition change after chemotherapy, endocrine therapy and androgen-deprivation therapy, and how it tracks with later cardiovascular risk.
Sniderman et al. JAMA Cardiology 2019
ApoB-first lipid management
Underpins our standard inclusion of ApoB and Lp(a) on every workup, not just LDL.
Reeve et al. JAMA Intern Med 2018
Deprescribing in survivorship recovery
Framework for structured tapering of supportive-care medications once treatment ends, coordinated with cardiac and metabolic monitoring.
Phillips et al. Sports Med 2016
Protein and resistance training for lean-mass recovery after treatment
Source of our 1.6 g/kg protein target and resistance-training Rx during caloric deficit.
Shepherd et al. 2017
DEXA in body composition surveillance
Validates serial DEXA as the gold standard for tracking fat vs. lean mass, used here to follow body-composition change after cancer treatment.
Full bibliography and clinical protocol library available to franchisees and credentialed clinicians via the Spark Academy portal.